242 related articles for article (PubMed ID: 12629823)
1. Medicare prescription plan, threat to AWP could impact the ESRD drug market.
Neumann ME
Nephrol News Issues; 2003 Jan; 17(2):16-7, 21. PubMed ID: 12629823
[No Abstract] [Full Text] [Related]
2. AWP reimbursement scrutinized by several states.
Carroll J
Manag Care; 2003 Apr; 12(4):11-2. PubMed ID: 12747021
[No Abstract] [Full Text] [Related]
3. Prescription drugs in Medicare and the ESRD program.
Powe NR
Semin Nephrol; 2000 Nov; 20(6):535-42. PubMed ID: 11111855
[TBL] [Abstract][Full Text] [Related]
4. Increasing generic drug use in Medicare Part D: the role of government.
Kohl H; Shrank WH
J Am Geriatr Soc; 2007 Jul; 55(7):1106-9. PubMed ID: 17608887
[No Abstract] [Full Text] [Related]
5. Lessons for Medicare Part D in the hemodialysis community.
Nayeem AI; Chertow GM
BMC Nephrol; 2006 Jul; 7():11. PubMed ID: 16824211
[TBL] [Abstract][Full Text] [Related]
6. MEDICARE Rx...help is on the way!
Frankenburger J
Colo Nurse; 2005 Sep; 105(3):22. PubMed ID: 16189957
[No Abstract] [Full Text] [Related]
7. Medicare prescription drug coverage (part D): challenges and opportunities.
Witten B
Nephrol News Issues; 2006 Aug; 20(9):14-6, 18. PubMed ID: 16916055
[No Abstract] [Full Text] [Related]
8. Potential impact of Medicare Part D in the end-stage renal disease population.
St Peter WL
Adv Chronic Kidney Dis; 2008 Apr; 15(2):140-6. PubMed ID: 18334238
[TBL] [Abstract][Full Text] [Related]
9. The importance of being first: evidence from Canadian generic pharmaceuticals.
Hollis A
Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
[TBL] [Abstract][Full Text] [Related]
10. Surviving change: Can the ESRD provisions in the SCHIP create a level playing field?
Gardner AV
Nephrol News Issues; 2007 Sep; 21(10):52-3. PubMed ID: 17918480
[No Abstract] [Full Text] [Related]
11. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
Patel UD; Davis MM
J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
[TBL] [Abstract][Full Text] [Related]
12. Best medicines for less: we compare drugs for what ails America.
Consum Rep; 2008 Jan; 73(1):27-9. PubMed ID: 18488284
[No Abstract] [Full Text] [Related]
13. Rising drug costs: the impact on dermatology.
Rico MJ
Skin Therapy Lett; 2000; 5(4):1-2,5. PubMed ID: 10785406
[TBL] [Abstract][Full Text] [Related]
14. Save green, go generic: be prepared to answer the $4 question.
Hansen D
S D Med; 2009 Nov; 62(11):436-7. PubMed ID: 20128174
[No Abstract] [Full Text] [Related]
15. Who should be paying for vitamin D analogues--Medicare or the patients?
Hall G
Nephrol Nurs J; 2006; 33(3):345-6, 351. PubMed ID: 16859205
[No Abstract] [Full Text] [Related]
16. GAO looks at bundling outside ESRD.
Neumann ME
Nephrol News Issues; 2011 Apr; 25(4):8. PubMed ID: 21542505
[No Abstract] [Full Text] [Related]
17. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
Openshaw MS
Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902
[TBL] [Abstract][Full Text] [Related]
18. [[Prescriptions for psychotropic drugs: results and comments on the 2007 prescription drug report].
Fritze J
Nervenarzt; 2008 Nov; 79(11):1337-45. PubMed ID: 19002733
[No Abstract] [Full Text] [Related]
19. [Prescriptions for psychotropic drugs: results and comments on the 2005 prescription drug report].
Fritze J
Nervenarzt; 2006 Mar; 77(3):376-83. PubMed ID: 17078120
[No Abstract] [Full Text] [Related]
20. MNT essential to plans for adding prescription drug benefit to Medicare.
Larson E
J Am Diet Assoc; 2000 Aug; 100(8):881-2. PubMed ID: 10955040
[No Abstract] [Full Text] [Related]
[Next] [New Search]
